LAUSR

Selumetinib is a mitogen‐activated protein kinase/extracellular signal‐regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off‐label for low‐grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose‐reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low‐dose isotretinoin when unresponsive to conventional therapies.